AJMCtv

Lili Brillstein Discusses Incorporating Social Determinants of Health Into Value-Based Care

Importance of Relapse Prevention in Schizophrenia

Akebia Therapeutics' CEO on Mechanisms of HIF-PHI Candidate

Complexity of Chronic Thromboembolic Pulmonary Hypertension

Dr John McMurray Explains the Heart Failure Benefits of Dapagliflozin in Diabetics and Non-Diabetics

Mavis Asiedu-Frimpong Explains How Medicaid Aims to Provide a Broad Spectrum of Personalized Care

Dr Peter McAllister Discusses Lessons Learned From COVID-19 for Migraine Treatment

Dr Deepak Bhatt Highlights Latest REDUCE-IT Data

Dr Timothy Yap: Rucaparib/Sacituzumab Govitecan Combo Effective Against Triple-Negative Disease

Dr Mark Fendrick Explains Bipartisan Appeal of Value-Based Insurance Design

Dr Ruth Ann Marrie Discusses Comorbidities in Multiple Sclerosis

Dr Stephen Silberstein Compares the Effects of Erenumab on Chronic, Episodic Migraine

Dr Peter McAllister Shares How COVID-19 Altered Patients' Migraine Symptoms

Whole-Person Health Care: Integrating Mental and Behavioral Health Into Primary Care

Dr Neal Jain on the Real-World Results of Dupilumab in Asthma

Dr Joshua Rein Offers Insights on Cannabis Use for Chronic Kidney Disease

Dr George Bakris Compares FIDELIO-DKD Renal Outcomes With Those of SGLT-2 Inhibitor Trials

Marc Boutin Examines the Underutilization of Patients

Value of Quality-of-Life Metrics

Dr Maura Abbott Explains How Vaccine Form Determines Patient Contraindications

Economic Burden of Atopic Dermatitis Treatment

Dr Stephen Silberstein on How Patients Are Reacting to CGRP Inhibitors

Understanding the Transition From RRMS to SPMS

Dr Jan Hillert on the Misclassification of SPMS as RRMS

Dr Jane F. Barlow Discusses Potential New Reimbursement Models for New, High-Cost Therapies

Dr Jonathan Avery on Causes, Consequences of Concurrent Mental Illness and Substance Use

Quality Metrics and Patient-Reported Outcomes

What is Interstitial Lung Disease?

Interstitial Lung Disease: Guidelines for Therapy

First-line Therapy for HR-positive, HER2-negative, mBC

The Nonpharmacological Treatment of Diabetes

Cardiovascular Risk Management

Economic Burden of Cardiovascular Disease

Dyslipidemia: Strategies Used to Reduce CV Risk

MDS Management: Challenges With Chemotherapy

Risk Assessment for Cardiovascular Disease

Role of Anemia in CKD

Dr. Matthew Budoff on the Benefits of Cardiac CT Use

Overview of Chronic Kidney Disease (CKD)

Dr Daniel Laroche Discusses Eye-Related Implications, Barriers to Eye Care Amid COVID-19

HIF Stabilizers: Management of Anemia in CKD

Future Treatment of Anemia in CKD: Impact of HIF Stabilizers

Steps to Reduce Racial Cancer Disparities Include Supporting Minority Doctors, Diversifying Trials

HIF Stabilizers for Anemia in CKD: Phase 3 Trials

Examining the Impact of Behavioral Health Costs on Overall Health Care Spending

Dr Milton Packer Discusses the Combined Impact of EMPEROR-Reduced, DAPA-HF

Dr Javed Butler on SGLT-2 Inhibitors' Role in Preventing HF

Dr Paulus Kirchhof Discusses EAST AFNET 4 Trial Results

Dr Stewart Factor on Implications, Treatment of OFF Periods in Parkinson Disease

Lili Brillstein Discusses Incorporating Social Determinants of Health Into Value-Based Care

Using Reimbursement Models to Overcome Oncology Care Gaps